Association between fibrinogen and fibrinogen γ' and atherosclerotic plaque morphology and composition in symptomatic carotid artery stenosis: Plaque-At-RISK study.


Journal

Thrombosis research
ISSN: 1879-2472
Titre abrégé: Thromb Res
Pays: United States
ID NLM: 0326377

Informations de publication

Date de publication:
May 2019
Historique:
received: 02 10 2018
revised: 16 01 2019
accepted: 23 02 2019
pubmed: 22 3 2019
medline: 7 1 2020
entrez: 22 3 2019
Statut: ppublish

Résumé

Von Willebrand Factor (VWF), ADAMTS13, fibrinogen and fibrinogen γ' are associated with an increased risk of ischemic stroke. Carotid atherosclerosis is an important risk factor for ischemic stroke. Characteristics of the vulnerable plaque; intraplaque hemorrhage (IPH), plaque ulceration and lipid-rich necrotic core (LRNC) can be visualized with imaging techniques. Since atherosclerosis might attribute to the association between coagulation factors and ischemic stroke risk, the aim of this study is to investigate the association between coagulation factors and atherosclerotic plaque characteristics in more detail. In 182 patients of the Plaque-At-RISK study (prospective multicenter cohort study) with a recent transient ischemic attack (TIA) or ischemic stroke and a symptomatic mild-to-moderate carotid artery stenosis, we measured VWF antigen (VWF:Ag), ADAMTS13 activity, fibrinogen (Clauss), and fibrinogen γ'. Presence of plaque ulceration, IPH volume and LRNC volume were determined by Multidetector-Row Computed Tomography (MDCTA, n = 160) and Magnetic Resonance Imaging (MRI, n = 172). Linear regression analysis was used to assess the association between imaging biomarkers and coagulation factors. VWF:Ag or ADAMTS13 levels were not significantly associated with plaque ulceration, IPH and LRNC. We found an inverse association between fibrinogen and fibrinogen γ' and IPH volume (B = -23.40 mm Fibrinogen and fibrinogen γ' are inversely associated with IPH volume and LRNC volume, independent of inflammation. clinicaltrials.govNCT01208025.

Identifiants

pubmed: 30897531
pii: S0049-3848(19)30075-1
doi: 10.1016/j.thromres.2019.02.030
pii:
doi:

Substances chimiques

Fibrinogens, Abnormal 0
fibrinogen gamma' 0
Fibrinogen 9001-32-5

Banques de données

ClinicalTrials.gov
['NCT01208025']

Types de publication

Clinical Trial Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

130-135

Informations de copyright

Copyright © 2019. Published by Elsevier Ltd.

Auteurs

A C van Dijk (AC)

Department of Radiology, Erasmus MC, University Medical Center Rotterdam, the Netherlands; Department of Neurology, Erasmus MC, University Medical Center Rotterdam, the Netherlands.

S J Donkel (SJ)

Department of Hematology, Erasmus MC, University Medical Center Rotterdam, the Netherlands.

T Zadi (T)

Department of Radiology, Erasmus MC, University Medical Center Rotterdam, the Netherlands.

M A H Sonneveld (MAH)

Department of Hematology, Erasmus MC, University Medical Center Rotterdam, the Netherlands.

F H B M Schreuder (FHBM)

Department of Clinical Neurophysiology, Maastricht University Medical Center, Maastricht, the Netherlands; Department of Neurology, Maastricht University Medical Center, Maastricht, the Netherlands.

M F Chohan (MF)

Department of Hematology, Erasmus MC, University Medical Center Rotterdam, the Netherlands.

P J Koudstaal (PJ)

Department of Neurology, Erasmus MC, University Medical Center Rotterdam, the Netherlands.

F W G Leebeek (FWG)

Department of Hematology, Erasmus MC, University Medical Center Rotterdam, the Netherlands.

R Saxena (R)

Department of Neurology, Maasstad hospital, Rotterdam, the Netherlands.

J Hendrikse (J)

Department of Radiology, University Medical Center Utrecht, Utrecht, the Netherlands.

M E Kooi (ME)

Department of Radiology and Nuclear Medicine, Maastricht University Medical Center, Maastricht, the Netherlands; Department of CARIM School for Cardiovascular Diseases, Maastricht University Medical Center, Maastricht, the Netherlands.

A van der Lugt (A)

Department of Radiology, Erasmus MC, University Medical Center Rotterdam, the Netherlands.

M P M de Maat (MPM)

Department of Hematology, Erasmus MC, University Medical Center Rotterdam, the Netherlands. Electronic address: m.demaat@erasmusmc.nl.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH